Your Source for Venture Capital and Private Equity Financings

Artax Biopharma Closes $26M Financing

2022-05-11
CAMBRIDGE, MA, Artax Biopharma, a clinical stage biotechnology company, has announced the close of a $26 million financing round.
Artax Biopharma, a clinical stage biotechnology company focused on transforming the treatment of T Cell-mediated pathologies, has announced the close of a $26 million financing round to develop AX-158, the Company's first oral small molecule immunomodulating agent. New investors, Eli Lilly and Company and Sound Bioventures, participated alongside existing investors Advent Life Sciences, Columbus Venture Partners, Belinda Termeer and other Company shareholders.

Artax Biopharma is a clinical-stage biotechnology company transforming T Cell-mediated disease treatment by developing innovative small molecules that modulate the immune system. Artax science holds broad potential to treat T Cell-mediated diseases such as autoimmune diseases; induced T cell pathologies (such as acute graft-versus-host disease and immune-oncology treatment-related adverse events); and T Cell malignancies, while simultaneously allowing the body to fight foreign pathogens.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading